Clinical trials: CUP
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Stroke, Apraxias
Trial Using CogWatch for Tea Making Training in Stroke Apraxia and Action Disorganisation Syndrome
Apraxia and action disorganization syndrome after stroke can disrupt activities of daily living (ADL). Occupational therapy has been effective in improving ADL performance, however, inclusion of multiple tasks means it is unclear…
- Trial name
- CogWatchTea (NCT04044911)
- Testing
- Task model (CogWatch)
- Volunteers
- 29 people
- Sponsor
- University of Birmingham
Sarcoidosis
A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis
Sarcoidosis is a systemic disease that results from granulomatous inflammation that involves multiple body organs. The diagnosis requires the presence of compatible clinicoradiological features along with histologic evidence that…
- Trial name
- NCT02405897
- Testing
- Cup forceps, Alligator forceps
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Periacetabular Tumor
A Randomized Controlled Study Evaluating Modified Cup Anteversion Placement in Prevention of Postoperative Dislocation in Patients Undergoing Acetabular Tumor Resection and Reconstruction
The purpose of this clinical study is to investigate whether patients who receive modified anteversion angle (( α-15°)±10°) of the acetabular cup have a lower risk of dislocation within one year after surgery, compared to…
- Trial name
- NCT05593146
- Testing
- modified anteversion angle placement(( α-15°)±10°), conventional anteversion angle placement ( α±10°)
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non-inflammatory Degenerative Joint Disease, Osteoarthritis
28mm Ceramic-on-Ceramic Total Hip Replacement Study
This study is intended to gather medium (0-5 years) and long-term (6-10 years) information regarding the performance and safety of the commercially available Ceramax™ Ceramic on Ceramic Total Hip System.
- Conditions
- Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Post-traumatic Arthritis
- Trial name
- COC28 (NCT01657435)
- Testing
- Ceramax Acetabular System
- Where
- 13 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- DePuy Orthopaedics
Osteoarthritis, Hip
MINIMA Stem With DELTA TT or DELTA ST-C Study
This study is aimed to provide a clinical and radiographic evaluation of 120 suitable subjects who underwent a total hip arthroplasty with MINIMA stem coupled with Delta TT or Delta ST-C cup.
- Trial name
- NCT06870123
- Testing
- TT cup and ST-C cup
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- Limacorporate S.p.a
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Unknown Primary, CUP
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted…
- Conditions
- Neoplasms, Unknown Primary, CUP, Metastatic Disease, Poorly Differentiated Adenocarcinoma
- Trial name
- NCT02628379
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Foundation Medicine